ReviewNanomedicine (London, England)2025
Inflammatory microenvironment-responsive MR imaging contrast agents.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is a hallmark of numerous acute and chronic diseases, presenting a unique opportunity for molecular imaging. Magnetic resonance imaging, while widely used for its excellent spatial resolution and soft tissue contrast, traditionally lacks the sensitivity and specificity needed to monitor dynamic biochemical processes. To address this gap, a new class of activatable MR imaging contrast agents has emerged - designed to respond selectively to inflammatory triggers such as acidic pH, reactive oxygen species, and proteolytic enzyme activity. This review highlights recent advances in the development of such smart contrast agents, emphasizing their molecular design, activation mechanisms, and preclinical validation. By enabling localized signal enhancement in response to inflammation, these agents offer the potential to improve diagnostic accuracy, stratify disease severity, and monitor therapeutic response with high spatial and temporal resolution. The translation of these agents into clinical practice will depend on continued optimization of stability, safety, and imaging performance across diverse disease models. We performed a literature search using PubMed and Google Scholar for articles published between January 2000 and February 2025 on activatable MR imaging contrast agents, redox-responsive nanoparticles, and imaging of inflammatory processes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.